DF
Duquesne Family Office
Activity from announced rounds
Activity in this selectionOct 20, 2026 · Sep 21, 2026
Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.
Recorded funding activity
Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.
- Rounds participated in
- 0
- Confirmed lead rounds
- — All roles disclosed
- New companies
- 0 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share
By stage
No activity in this selection.
By primary sector
No activity in this selection.
By country
No activity in this selection.
Rounds
0 in this selectionNo rounds match this selection.